Cuu Long Pharmaceutical JSC (HOSE:DCL)
Vietnam · Delayed Price · Currency is VND 44,400
+200 (0.45%)
At close: Nov 3, 2026
HOSE:DCL Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,321,438 | 1,321,589 | 1,306,797 | 1,143,946 | 1,015,686 | 703,634 | |
Revenue Growth | -9.45% | 1.13% | 14.24% | 12.63% | 44.35% | 4.83% |
Cost of Revenue | 1,140,716 | 1,117,345 | 1,102,093 | 934,032 | 733,585 | 493,482 |
Gross Profit | 180,722 | 204,244 | 204,704 | 209,914 | 282,100 | 210,152 |
Selling, General & Admin | 153,240 | 145,758 | 144,874 | 139,188 | 153,815 | 123,371 |
Operating Expenses | 153,240 | 145,758 | 144,874 | 139,188 | 153,815 | 123,371 |
Operating Income | 27,482 | 58,485 | 59,830 | 70,726 | 128,285 | 86,781 |
Interest Expense | -61,099 | -49,129 | -25,494 | -30,530 | -39,627 | -36,264 |
Interest & Investment Income | 7,899 | 31,824 | 34,279 | 39,667 | 52,712 | 51,929 |
Currency Exchange Gain (Loss) | -20.92 | -231.77 | 152.37 | -2,705 | 77.03 | -90.68 |
Other Non Operating Income (Expenses) | 23,825 | -8,539 | 9.56 | 953.02 | 94.19 | 6,058 |
EBT Excluding Unusual Items | -1,915 | 32,410 | 68,777 | 78,111 | 141,542 | 108,412 |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 1,872 |
Legal Settlements | 2,302 | 2,302 | - | - | - | - |
Pretax Income | 386.67 | 34,711 | 68,777 | 78,111 | 141,542 | 110,284 |
Income Tax Expense | 14,562 | 14,620 | 14,631 | 15,976 | 28,628 | 22,528 |
Earnings From Continuing Operations | -14,175 | 20,091 | 54,145 | 62,134 | 112,914 | 87,756 |
Minority Interest in Earnings | -643.85 | -574.7 | -574.4 | -416.96 | -1,273 | -1,796 |
Net Income | -14,819 | 19,516 | 53,571 | 61,717 | 111,641 | 85,961 |
Preferred Dividends & Other Adjustments | - | - | 2,000 | 2,000 | 3,000 | 2,000 |
Net Income to Common | -14,819 | 19,516 | 51,571 | 59,717 | 108,641 | 83,961 |
Net Income Growth | - | -62.16% | -13.64% | -45.03% | 29.39% | 30.61% |
Shares Outstanding (Basic) | 19 | 73 | 73 | 73 | 70 | 57 |
Shares Outstanding (Diluted) | 19 | 73 | 73 | 73 | 70 | 57 |
Shares Change | -74.36% | - | - | 4.11% | 22.02% | 1.17% |
EPS (Basic) | -790.59 | 267.20 | 706.06 | 817.59 | 1548.46 | 1460.20 |
EPS (Diluted) | -791.36 | 267.00 | 706.00 | 817.59 | 1548.00 | 1460.00 |
EPS Growth | - | -62.18% | -13.65% | -47.18% | 6.03% | 29.09% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -54,129 | -40,249 | -103,037 | -200,343 | -683,099 | -123,174 |
Free Cash Flow Per Share | -2887.72 | -551.05 | -1410.67 | -2742.89 | -9736.25 | -2142.18 |
Gross Margin | 13.68% | 15.45% | 15.67% | 18.35% | 27.77% | 29.87% |
Operating Margin | 2.08% | 4.42% | 4.58% | 6.18% | 12.63% | 12.33% |
Profit Margin | -1.12% | 1.48% | 3.95% | 5.22% | 10.70% | 11.93% |
Free Cash Flow Margin | -4.10% | -3.05% | -7.89% | -17.51% | -67.25% | -17.51% |
EBITDA | 83,032 | 111,490 | 98,088 | 109,004 | 166,420 | 121,054 |
EBITDA Margin | 6.28% | 8.44% | 7.51% | 9.53% | 16.38% | 17.20% |
D&A For EBITDA | 55,550 | 53,005 | 38,258 | 38,278 | 38,135 | 34,273 |
EBIT | 27,482 | 58,485 | 59,830 | 70,726 | 128,285 | 86,781 |
EBIT Margin | 2.08% | 4.42% | 4.58% | 6.18% | 12.63% | 12.33% |
Effective Tax Rate | 3765.95% | 42.12% | 21.27% | 20.45% | 20.23% | 20.43% |
Revenue as Reported | 1,321,438 | 1,321,589 | 1,306,797 | - | 1,015,686 | 703,634 |